CD44 expression in the stromal matrix of colorectal cancer: Association with prognosis

Koh Furuta, Marianna Zahurak, Steven N. Goodman, Stanley R. Hamilton, Thomas August

Research output: Contribution to journalArticle

Abstract

CD44, a cell hyaluronate receptor, is implicated in the metastatic behavior of some cancer cells. This study analyzed CD44 expression in topographic tissue sites of colorectal cancers to determine its association with patient survival and clinicopathological characteristics. Immunohistochemical localization of the core CD44 and the v6 splice variant domains was examined by use of paraffin-fixed sections from 133 stage II or IIi colorectal cancers that previously had been evaluated for other diagnostic markers. Expression in malignant epithelium, stromal matrix, and stromal cells was compared to patient survival by univariate, multivariate, and bootstrap (reproducibility) analysis. Core CD44 staining was present in the malignant epithelium of 85% of tumors, the stromal matrix of 90%, and the stromal cells of 98%. The v6 splice variant domain was present in the epithelium of 77% of tumors but was less frequent in the stromal matrix (12%; P <0.001) and stromal cells (17%; P <0.001). Absence of core CD44 immunoreactivity in the stromal matrix was associated with increased death rate (hazard ratio, 2.4; 95% confidence interval, 1.2-4.8; P = 0.02), making this one of the most significant adverse prognostic variables, along with an age of 60 years or older, poor differentiation of the cancer, extramural venous invasion, chromosome 18q allelic loss, and nonwhite race. This study shows that core CD44 and v6 splice variant antigens are differentially expressed in the epithelium and stroma of colorectal cancers. A model that includes core CD44 immunoreactivity in stromal matrix along with other prognostic factors may improve identification of high-risk and low-risk patients.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalClinical Cancer Research
Volume4
Issue number1
StatePublished - Jan 1998

Fingerprint

Colorectal Neoplasms
Epithelium
Stromal Cells
Neoplasms
Survival
Loss of Heterozygosity
Paraffin
Chromosomes
Confidence Intervals
Staining and Labeling
Antigens
Mortality

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Furuta, K., Zahurak, M., Goodman, S. N., Hamilton, S. R., & August, T. (1998). CD44 expression in the stromal matrix of colorectal cancer: Association with prognosis. Clinical Cancer Research, 4(1), 21-29.

CD44 expression in the stromal matrix of colorectal cancer : Association with prognosis. / Furuta, Koh; Zahurak, Marianna; Goodman, Steven N.; Hamilton, Stanley R.; August, Thomas.

In: Clinical Cancer Research, Vol. 4, No. 1, 01.1998, p. 21-29.

Research output: Contribution to journalArticle

Furuta, K, Zahurak, M, Goodman, SN, Hamilton, SR & August, T 1998, 'CD44 expression in the stromal matrix of colorectal cancer: Association with prognosis', Clinical Cancer Research, vol. 4, no. 1, pp. 21-29.
Furuta K, Zahurak M, Goodman SN, Hamilton SR, August T. CD44 expression in the stromal matrix of colorectal cancer: Association with prognosis. Clinical Cancer Research. 1998 Jan;4(1):21-29.
Furuta, Koh ; Zahurak, Marianna ; Goodman, Steven N. ; Hamilton, Stanley R. ; August, Thomas. / CD44 expression in the stromal matrix of colorectal cancer : Association with prognosis. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 1. pp. 21-29.
@article{8f91d1aed18d4a94b1387bd63e79c238,
title = "CD44 expression in the stromal matrix of colorectal cancer: Association with prognosis",
abstract = "CD44, a cell hyaluronate receptor, is implicated in the metastatic behavior of some cancer cells. This study analyzed CD44 expression in topographic tissue sites of colorectal cancers to determine its association with patient survival and clinicopathological characteristics. Immunohistochemical localization of the core CD44 and the v6 splice variant domains was examined by use of paraffin-fixed sections from 133 stage II or IIi colorectal cancers that previously had been evaluated for other diagnostic markers. Expression in malignant epithelium, stromal matrix, and stromal cells was compared to patient survival by univariate, multivariate, and bootstrap (reproducibility) analysis. Core CD44 staining was present in the malignant epithelium of 85{\%} of tumors, the stromal matrix of 90{\%}, and the stromal cells of 98{\%}. The v6 splice variant domain was present in the epithelium of 77{\%} of tumors but was less frequent in the stromal matrix (12{\%}; P <0.001) and stromal cells (17{\%}; P <0.001). Absence of core CD44 immunoreactivity in the stromal matrix was associated with increased death rate (hazard ratio, 2.4; 95{\%} confidence interval, 1.2-4.8; P = 0.02), making this one of the most significant adverse prognostic variables, along with an age of 60 years or older, poor differentiation of the cancer, extramural venous invasion, chromosome 18q allelic loss, and nonwhite race. This study shows that core CD44 and v6 splice variant antigens are differentially expressed in the epithelium and stroma of colorectal cancers. A model that includes core CD44 immunoreactivity in stromal matrix along with other prognostic factors may improve identification of high-risk and low-risk patients.",
author = "Koh Furuta and Marianna Zahurak and Goodman, {Steven N.} and Hamilton, {Stanley R.} and Thomas August",
year = "1998",
month = "1",
language = "English (US)",
volume = "4",
pages = "21--29",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - CD44 expression in the stromal matrix of colorectal cancer

T2 - Association with prognosis

AU - Furuta, Koh

AU - Zahurak, Marianna

AU - Goodman, Steven N.

AU - Hamilton, Stanley R.

AU - August, Thomas

PY - 1998/1

Y1 - 1998/1

N2 - CD44, a cell hyaluronate receptor, is implicated in the metastatic behavior of some cancer cells. This study analyzed CD44 expression in topographic tissue sites of colorectal cancers to determine its association with patient survival and clinicopathological characteristics. Immunohistochemical localization of the core CD44 and the v6 splice variant domains was examined by use of paraffin-fixed sections from 133 stage II or IIi colorectal cancers that previously had been evaluated for other diagnostic markers. Expression in malignant epithelium, stromal matrix, and stromal cells was compared to patient survival by univariate, multivariate, and bootstrap (reproducibility) analysis. Core CD44 staining was present in the malignant epithelium of 85% of tumors, the stromal matrix of 90%, and the stromal cells of 98%. The v6 splice variant domain was present in the epithelium of 77% of tumors but was less frequent in the stromal matrix (12%; P <0.001) and stromal cells (17%; P <0.001). Absence of core CD44 immunoreactivity in the stromal matrix was associated with increased death rate (hazard ratio, 2.4; 95% confidence interval, 1.2-4.8; P = 0.02), making this one of the most significant adverse prognostic variables, along with an age of 60 years or older, poor differentiation of the cancer, extramural venous invasion, chromosome 18q allelic loss, and nonwhite race. This study shows that core CD44 and v6 splice variant antigens are differentially expressed in the epithelium and stroma of colorectal cancers. A model that includes core CD44 immunoreactivity in stromal matrix along with other prognostic factors may improve identification of high-risk and low-risk patients.

AB - CD44, a cell hyaluronate receptor, is implicated in the metastatic behavior of some cancer cells. This study analyzed CD44 expression in topographic tissue sites of colorectal cancers to determine its association with patient survival and clinicopathological characteristics. Immunohistochemical localization of the core CD44 and the v6 splice variant domains was examined by use of paraffin-fixed sections from 133 stage II or IIi colorectal cancers that previously had been evaluated for other diagnostic markers. Expression in malignant epithelium, stromal matrix, and stromal cells was compared to patient survival by univariate, multivariate, and bootstrap (reproducibility) analysis. Core CD44 staining was present in the malignant epithelium of 85% of tumors, the stromal matrix of 90%, and the stromal cells of 98%. The v6 splice variant domain was present in the epithelium of 77% of tumors but was less frequent in the stromal matrix (12%; P <0.001) and stromal cells (17%; P <0.001). Absence of core CD44 immunoreactivity in the stromal matrix was associated with increased death rate (hazard ratio, 2.4; 95% confidence interval, 1.2-4.8; P = 0.02), making this one of the most significant adverse prognostic variables, along with an age of 60 years or older, poor differentiation of the cancer, extramural venous invasion, chromosome 18q allelic loss, and nonwhite race. This study shows that core CD44 and v6 splice variant antigens are differentially expressed in the epithelium and stroma of colorectal cancers. A model that includes core CD44 immunoreactivity in stromal matrix along with other prognostic factors may improve identification of high-risk and low-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=0031882947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031882947&partnerID=8YFLogxK

M3 - Article

C2 - 9516948

AN - SCOPUS:0031882947

VL - 4

SP - 21

EP - 29

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -